In addition, Shang et al. found that PTPRD and PTPRT mutations may be a biomarker for predicting immunotherapy in pan-cancer, but the role of PTPRD mutation in NSCLC has not been analyzed separately [39]. This evidence concerns the gene PTPRD and non-small cell lung carcinoma.